Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

NCT04713592 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Placebo for Risankizumab
DRUG: Risankizumab

Sponsor

AbbVie